Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug73 | 55 Gy Radiation Therapy Wiki | 0.71 |
drug71 | 50 Gy Radiation Therapy Wiki | 0.71 |
drug1523 | Entinostat Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D018288 | Carcinoma, Small Cell NIH | 0.50 |
D055752 | Small Cell Lung Carcinoma NIH | 0.41 |
D006258 | Head and Neck Neoplasms NIH | 0.32 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0030357 | Small cell lung carcinoma HPO | 0.41 |
HP:0012288 | Neoplasm of head and neck HPO | 0.32 |
HP:0002664 | Neoplasm HPO | 0.10 |
Navigate: Correlations HPO
There are 2 clinical trials
Locoregional failure remains the principal mode of mortality in head and neck squamous cell carcinoma (HNSCC) treated with conventional chemoradiation therapy. Magnetic resonance-guided radiation therapy (MRgRT) allows for adaptive radiation dose escalation based on tumor response and may improve therapeutic outcomes while limiting toxicities. This protocol evaluates a novel framework for radiation delivery with concurrent atezolizumab in patients with advanced HNSCC. Dose-Escalated Hypofractionated Adaptive Radiotherapy (DEHART) modifies radiation dose using MRgRT by escalating radiation dose to residual tumor while deescalating radiation dose to areas of tumor regression.
Description: This measure is the number of subjects experiencing a dose-limiting toxicity. A dose-limiting toxicity is defined as an inability to complete radiation treatment within 30 days of the start of radiotherapy that is not deemed to be related to disease progression; OR an unacceptable toxicity within one year of treatment (Grade 4+ toxicity) that is probably or definitely related to radiation treatment as determined by the treating physician or a death within one year of treatment that is probably or definitely related to treatment.
Measure: Incidence of Dose-Limiting Toxicities Time: 12 monthsDescription: This measure is the highest radiation dose at which there is a 30% or more rate of dose-limiting toxicity up to 12 months after completion of radiation treatment using the TITE-CRM design.
Measure: Maximum Tolerated Radiation Dose Time: 12 monthsDescription: This measure is the number of subjects alive at 1 year following the conclusion of scheduled radiation therapy.
Measure: Overall Survival Time: 1 yearDescription: This measure is the number of subjects showing disease progression in the head and neck by RECIST criteria.
Measure: Locoregional progression Time: 1 yearDescription: This measure is the change in gross tumor volume for each subject as contoured on pre-treatment (baseline) and treatment 6 imaging scans.
Measure: Gross Tumor Volume at Radiation Fraction 6 (Change from Baseline) Time: 6th Radiation Fraction (approximately 1 week)Description: This measure is the change in gross tumor volume for each subject as contoured on pre-treatment (baseline) and treatment 11 imaging scans.
Measure: Gross Tumor Volume at Radiation Fraction 11 (Change from Baseline) Time: 11th Radiation Fraction (approximately 2 weeks)Description: MD Anderson Symptom Inventory for Head and Neck tool comprises 11-item Likert-style questions assessing 9 symptoms relevant to head and neck cancer. Responses range from 0 (no 'symptom') to 10 (severe 'symptom').
Measure: MD Anderson Symptom Inventory for Head and Neck (MDASI-HN) Score Time: Baseline; weeks 1, 2, and 3 during radiotherapy; weeks 1, 2, 3, 4 and months 3, 6, 9 and 12 following fraction 1Description: This measure is the score for the "mucus in the mouth and throat" domain items of the MD Anderson Symptom Inventory tool. The measure is derived from a subset of 11-item Likert-style questions presented in the full inventory tool that assess symptoms relevant to mucus in the mouth and throat. Responses range from 0 (no 'symptom') to 10 (severe 'symptom').
Measure: MD Anderson Symptom Inventory for Head and Neck Domain Score (Mucus in the Mouth and Throat) Time: Baseline; weeks 1, 2, and 3 during radiotherapy; weeks 1, 2, 3, 4 and months 3, 6, 9 and 12 following fraction 1Description: This measure is the score for the "difficulty swallowing or chewing" domain items of the MD Anderson Symptom Inventory tool. The measure is derived from a subset of 11-item Likert-style questions presented in the full inventory tool that assess symptoms relevant to swallowing or chewing. Responses range from 0 (no 'symptom') to 10 (severe 'symptom').
Measure: MD Anderson Symptom Inventory for Head and Neck Domain Score (Difficulty Swallowing or Chewing) Time: Baseline; weeks 1, 2, and 3 during radiotherapy; weeks 1, 2, 3, 4 and months 3, 6, 9 and 12 following fraction 1Description: This measure is the score for the "choking or coughing" domain items of the MD Anderson Symptom Inventory tool. The measure is derived from a subset of 11-item Likert-style questions presented in the full inventory tool that assess symptoms relevant to coughing or a sensation of choking. Responses range from 0 (no 'symptom') to 10 (severe 'symptom').
Measure: MD Anderson Symptom Inventory for Head and Neck Domain Score (Choking or Coughing) Time: Baseline; weeks 1, 2, and 3 during radiotherapy; weeks 1, 2, 3, 4 and months 3, 6, 9 and 12 following fraction 1Description: This measure is the score for the "difficulty with voice or speech" domain items of the MD Anderson Symptom Inventory tool. The measure is derived from a subset of 11-item Likert-style questions presented in the full inventory tool that assess symptoms relevant to voice production and quality or speech. Responses range from 0 (no 'symptom') to 10 (severe 'symptom').
Measure: MD Anderson Symptom Inventory for Head and Neck Domain Score (Difficulty with Voice or Speech) Time: Baseline; weeks 1, 2, and 3 during radiotherapy; weeks 1, 2, 3, 4 and months 3, 6, 9 and 12 following fraction 1Description: This measure is the score for the "skin pain, burning or rash" domain items of the MD Anderson Symptom Inventory tool. The measure is derived from a subset of 11-item Likert-style questions presented in the full inventory tool that assess symptoms relevant to the sensation of pain and/or burning and/or presence of a rash in irradiated areas of the skin. Responses range from 0 (no 'symptom') to 10 (severe 'symptom').
Measure: MD Anderson Symptom Inventory for Head and Neck Domain Score (Skin Pain, Burning or Rash) Time: Baseline; weeks 1, 2, and 3 during radiotherapy; weeks 1, 2, 3, 4 and months 3, 6, 9 and 12 following fraction 1Description: This measure is the score for the "constipation" domain items of the MD Anderson Symptom Inventory tool. The measure is derived from a subset of 11-item Likert-style questions presented in the full inventory tool that assess symptoms relevant to constipation and bowel function. Responses range from 0 (no 'symptom') to 10 (severe 'symptom').
Measure: MD Anderson Symptom Inventory for Head and Neck Domain Score (Constipation) Time: Baseline; weeks 1, 2, and 3 during radiotherapy; weeks 1, 2, 3, 4 and months 3, 6, 9 and 12 following fraction 1Description: This measure is the score for the "problems with tasting food" domain items of the MD Anderson Symptom Inventory tool. The measure is derived from a subset of 11-item Likert-style questions presented in the full inventory tool that assess symptoms relevant to the sensation of taste. Responses range from 0 (no 'symptom') to 10 (severe 'symptom').
Measure: MD Anderson Symptom Inventory for Head and Neck Domain Score (Problems with Tasting Food) Time: Baseline; weeks 1, 2, and 3 during radiotherapy; weeks 1, 2, 3, 4 and months 3, 6, 9 and 12 following fraction 1Description: This measure is the score for the "mouth or throat sores" domain items of the MD Anderson Symptom Inventory tool. The measure is derived from a subset of 11-item Likert-style questions presented in the full inventory tool that assess symptoms relevant to sores or lesions present in the mouth and throat. Responses range from 0 (no 'symptom') to 10 (severe 'symptom').
Measure: MD Anderson Symptom Inventory for Head and Neck Domain Score (Mouth or Throat Sores) Time: Baseline; weeks 1, 2, and 3 during radiotherapy; weeks 1, 2, 3, 4 and months 3, 6, 9 and 12 following fraction 1Description: This measure is the score for the "problems with teeth or gums" domain items of the MD Anderson Symptom Inventory tool. The measure is derived from a subset of 11-item Likert-style questions presented in the full inventory tool that assess symptoms relevant to oral health particularly the teeth and gums. Responses range from 0 (no 'symptom') to 10 (severe 'symptom').
Measure: MD Anderson Symptom Inventory for Head and Neck Domain Score (Problems with Teeth or Gums) Time: Baseline; weeks 1, 2, and 3 during radiotherapy; weeks 1, 2, 3, 4 and months 3, 6, 9 and 12 following fraction 1Description: This measure comprises a single five-item, Likert-style question with responses ranging from 'Strongly Agree' to 'Strongly Disagree'. A higher score ('Strongly Agree') corresponds to a worse outcome.
Measure: MD Anderson Dysphagia Inventory Global Score Time: Baseline; weeks 1, 2, and 3 during radiotherapy; weeks 1, 2, 3, 4 and months 3, 6, 9 and 12 following fraction 1Description: This measure comprises 19 five-item, Likert-style questions with responses ranging from 'Strongly Agree' to 'Strongly Disagree'. Questions are worded such that higher scores ('Strongly Agree') corresponds to worse traits or more severe symptoms.
Measure: MD Anderson Dysphagia Inventory Composite Score Time: Baseline; weeks 1, 2, and 3 during radiotherapy; weeks 1, 2, 3, 4 and months 3, 6, 9 and 12 following fraction 1Description: This measure is the score for the "emotional" domain comprising a subset of five-item, Likert-style questions of the MD Anderson Dysphagia Inventory Composite tool that assesses symptoms relevant to emotional health. Responses range from 'Strongly Agree' to 'Strongly Disagree'. Questions are worded such that higher scores ('Strongly Agree') correspond to worse traits or more severe symptoms.
Measure: MD Anderson Dysphagia Inventory Score (Emotional) Time: Baseline; weeks 1, 2, and 3 during radiotherapy; weeks 1, 2, 3, 4 and months 3, 6, 9 and 12 following fraction 1Description: This measure is the score for the "functional" domain comprising a subset of five-item, Likert-style questions of the MD Anderson Dysphagia Inventory Composite tool that assesses symptoms relevant to the ability to function in daily life activities. Responses range from 'Strongly Agree' to 'Strongly Disagree'. Questions are worded such that higher scores ('Strongly Agree') correspond to worse traits or more severe symptoms.
Measure: MD Anderson Dysphagia Inventory Score (Functional) Time: Baseline; weeks 1, 2, and 3 during radiotherapy; weeks 1, 2, 3, 4 and months 3, 6, 9 and 12 following fraction 1Description: This measure is the score for the "physical" domain comprising a subset of five-item, Likert-style questions of the MD Anderson Dysphagia Inventory Composite tool that assesses symptoms relevant to the ability to perform physical activities. Responses range from 'Strongly Agree' to 'Strongly Disagree'. Questions are worded such that higher scores ('Strongly Agree') correspond to worse traits or more severe symptoms.
Measure: MD Anderson Dysphagia Inventory Score (Physical) Time: Baseline; weeks 1, 2, and 3 during radiotherapy; weeks 1, 2, 3, 4 and months 3, 6, 9 and 12 following fraction 1Description: The Eating Assessment Tool comprises 10 five-item, Likert-style questions querying various aspects of swallowing. Responses range from 0 (No problem) to 4 (Severe problem). The total of the responses represents the EAT-10 score. Higher numbers indicate poorer swallowing ability.
Measure: Eating Assessment Tool (EAT-10) Score Time: Baseline, and months 3 and 6 following fraction 1Description: The Functional Oral Intake Scale is a clinician-completed ordinal rating scale ranging from 1 (No oral intake) to 7 (Total oral intake with no restrictions). Higher numbers indicate more favorable feeding capability.
Measure: Functional Oral Intake Scale (FOIS) Time: Baseline, and months 3 and 6 following fraction 1Description: The DIGEST grade is a five-item modified barium swallow scale for grading pharyngeal dysphagia as a toxicity endpoint. The DIGEST grade responses are: grade 1= mild, grade 2= moderate, grade 3= severe, and grade 4= life threatening pharyngeal dysphagia.
Measure: Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) Grade Time: Baseline, and months 3 and 6 following fraction 1This phase I trial identifies the best dose and side effects of entinostat in combination with atezolizumab, carboplatin and etoposide for the treatment of previously untreated aggressive lung cancer that has spread (extensive-stage small cell lung cancer). Entinostat and etoposide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving entinostat in combination with atezolizumab, carboplatin and etoposide may work better than atezolizumab, carboplatin and etoposide alone.
Description: The Bayesian optimal interval (BOIN) design will be used to find the MTD based on safety.
Measure: Maximum tolerated dose (MTD) Time: Up to 21 daysDescription: Defined by Common Terminology Criteria for Adverse Events version 5.0. Will be summarized by frequency and magnitude.
Measure: Grade 3/4 adverse event rate Time: Up to 30 daysDescription: The proportion of participants who receive 3 or more cycles of the combination, will be calculated with a 90% confidence interval.
Measure: Number of cycles received of the combination of entinostat, atezolizumab, carboplatin, and etoposide Time: Up to cycle 4 (1 cycle = 21 days)Description: Defined as the proportion of patients alive and without disease progression after 9 months from study enrollment. The 9 month PFS rate will be estimated with a 90% confidence interval. The Kaplan Meier estimator will be used to estimate survival curves.
Measure: 9-month progression free survival (PFS) rate Time: 9 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports